换一批
换一批第三代表皮生长因子受体酪氨酸激酶抑制剂对非小细胞肺癌的作用机制和临床疗效
Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer
摘要表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)是非小细胞肺癌(NSCLC)EGFR突变患者的标准治疗.但使用TKIs后会产生耐药,其中最主要的原因是发生了T790M突变.第三代EGFR-TKIs对激活突变型(EGFR敏感性突变)和耐药突变型(T790M突变)具有高效选择性.文章就第三代EGFR-TKIs药物对NSCLC患者的作用机制和临床疗效进行了总结和展望.
更多相关知识
abstractsEpidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations.However, most of patients will develop resistance to TKIs treatment due to the emergence of the T790M mutation.The third-generation EGFR-TKI is highly selective and efficient for activating mutants (EGFR sensitive mutations) and resistance mutant (T790M+).This review summarizes the mechanism and clinical efficacy of the third-generation EGFR-TKI in NSCLC patients.
More相关知识
关键词
癌,非小细胞肺表皮生长因子受体酪氨酸激酶抑制剂耐药性T790M突变药物疗法Carcinoma,non-small cell lungEpidermal growth factor receptor-tyrosine kinase inhibitorsDrug resistanceT790M mutationDrug therapy
主题词
受体, 表皮生长因子(Receptor, Epidermal Growth Factor)酪氨酸(Tyrosine)突变(Mutation)癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung)癌(Carcinoma)
栏目名称
专题综论
DOI
10.3760/cma.j.issn.0253-3766.2017.06.001
发布时间
2017-07-19
基金项目
上海市医学引导类科技项目
The Project of the Science and Technology Commission of Shanghai Municipality
- 浏览375
- 被引2
- 下载662
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
